Loading...

LONA LEONABIO INC Company Mergers 8-K Filing

LNB

LN

LEONABIO INC

(LONA)

2026 8-K

Financial Results Report

Acquisition Update

Financial Results Report

Stockholder Approvals

Name Change Announcement

Funding and Licensing

Private Placement Financing

Financial Results Report

Compliance Regained

Reverse Stock Split

Reverse Stock Splits

Financial Statements

Stock Listing Transfer

Financial Results

Financial Results

Nasdaq Compliance Notice

Executive Changes

Workforce Reduction

Clinical Trial Results

Earnings Report

Annual Meeting Results

Settlement Approval

Financial Results

Financial Results and Induc...

Financial Condition Announc...

Earnings Reports

Earnings Reports

Management Change

Earnings Reports

Financial Results Announcement

Equity Offering

External Links:

LeonaBio, Inc. filed an amendment to its 8-K on March 31, 2026, to report changes regarding the acquisition of Sermonix, which included cash expenditures of approximately $14 million in 2023, $12 million in 2024, and an expected $45 million in 2026 for the ELAINE-3 study.

AI Assistant

LEONABIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.